Freedom Broker raises Biogen stock price target on strong results

Freedom Broker raised its Biogen price target to $275 from $255 and maintained a Buy rating, citing resilient products and a positive contribution from the Apellis acquisition. Biogen’s Q3 2026 adjusted EPS of $2.62 exceeded the $2.02 forecast, while revenue of $2.8B topped the $2.64B forecast; Apellis synergies also lifted the low end of full-year EPS guidance, though the company reiterated its revenue outlook. The broker cautioned that product-specific one-time benefits will create headwinds in Q4 2026, but argued the earnings beat was not driven solely by those benefits.

Analysis

The setup is less about the headline EPS beat than about whether recurring growth can absorb the Q4 comparison created by product-specific benefits. Apellis synergies can support earnings even if revenue growth stays muted, but investors should separate cost takeout from durable demand: synergy delivery can lift margins only so far, while a revenue outlook that is not raised leaves execution dependent on the growth portfolio. Leqembi IQLIK offers a potential catalyst, but uptake and persistence—not launch commentary—will determine whether it offsets pressure elsewhere; Lilly’s competing Alzheimer’s therapy raises the bar for differentiation and adoption.

Near term, the 65% trailing rally and proximity to the 52-week high leave BIIB exposed to a “good quarter, harder next quarter” reaction if Q4 guidance or the earnings bridge disappoints. The raised $275 target implies limited further upside from the cited share price, while the spread among broker targets cautions against treating upgrades as confirmation of intrinsic value. Over 1–3 months, focus on Q4 guidance and evidence that underlying product demand, excluding one-offs, is holding. Over 6–18 months, the thesis depends on sustained rare-disease/specialized-immunology contribution, realized Apellis synergies, and meaningful Leqembi adoption. The contrarian upside is that conservative guidance may understate recurring earnings power; that is not yet independently demonstrated. Falsify the cautious stance if management raises revenue expectations on organic demand and delivers the synergy contribution without deterioration in core-product trends.

Key Decisions for Investors

• Do not chase BIIB solely on analyst target increases at current levels; the post-rally risk/reward appears more dependent on execution than on further multiple expansion. Reassess on a pullback or after the next guidance update.
• Track the Q4 earnings bridge: separate one-time product benefits from recurring product revenue and Apellis synergies. A miss against the underlying run rate, or renewed revenue-guidance pressure, would strengthen the case to reduce exposure.
• Treat Leqembi IQLIK as a catalyst to verify, not a booked offset: monitor adoption and persistence data alongside competitive uptake from Eli Lilly. Strong, sustained adoption would improve the medium-term growth case; weak conversion would undermine it.
• A more constructive entry signal would be evidence of revenue resilience plus delivered synergies without deterioration in core-product demand. Conversely, a guidance cut or weaker recurring-product trends would falsify the upside thesis and could make the recent rally vulnerable.